Vivo Capital, LLC
An institutional investment manager in Palo Alto, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1674712.
- Reported value$1.10bn
- Positions47
Holdings: 47 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Trevi Therapeutics IncTRVI | Common | 89532M101 | 95.0 | 8.7% | 5,094,668 | Unchanged | |
| Praxis Precision MedicinesPRAX | Common | 74006W207 | 90.8 | 8.3% | 271,116 | Reduced−67,779 | |
| Erasca IncERAS | Common | 29479A108 | 75.6 | 6.9% | 4,127,412 | Reduced−8,024,068 | |
| Arrivent BioPharma IncAVBP | Common | 04272N102 | 58.4 | 5.3% | 1,682,097 | Added+796,181 | |
| Abivax SA - ADRABVX | SPONSORED ADS | 00370M103 | 55.3 | 5.0% | 414,899 | Added+175,360 | |
| Tango Therapeutics IncTNGX | Common | 87583X109 | 43.1 | 3.9% | 1,379,769 | Reduced−775,011 | |
| Corvus Pharmaceuticals IncCRVS | Common | 221015100 | 41.9 | 3.8% | 2,805,816 | Unchanged | |
| Bright Minds Biosciences IncDRUG | Common | 10919W405 | 39.1 | 3.6% | 557,172 | Unchanged | |
| Sinovac Biotech Ltd. | SHS | P8696W104 | 38.2 | 3.5% | 5,903,000 | Unchanged | |
| Tenax Therapeutics IncTENX | Common | 88032L605 | 36.4 | 3.3% | 2,500,000 | Added+2,291,667 | |
| Aclaris Therapeutics, Inc.ACRS | Common | 00461U105 | 35.4 | 3.2% | 6,694,637 | Added+27,971 | |
| Dyne Therapeutics IncDYN | Common | 26818M108 | 34.6 | 3.2% | 1,557,466 | Unchanged | |
| Dianthus Therapeutics IncDNTH | Common | 252828108 | 34.5 | 3.2% | 353,998 | Unchanged | |
| Alto Neuroscience IncANRO | Common | 02157Q109 | 31.9 | 2.9% | 1,208,858 | Added+173,307 | |
| DBV Technologies SADBVT | SPONSORED ADS | 23306J309 | 30.3 | 2.8% | 1,844,758 | Reduced−822,811 | |
| SAB Biotherapeutics IncSABS | Common | 78397T202 | 28.5 | 2.6% | 7,299,909 | Reduced−4,120,091 | |
| Moonlake ImmunotherapeuticsMLTX | Class A ORD | 61559X104 | 27.3 | 2.5% | 1,400,000 | Added+400,000 | |
| LB Pharmaceuticals IncLBRX | Common | 50180M108 | 26.0 | 2.4% | 800,000 | Unchanged | |
| Minerva Neurosciences IncNERV | Common | 603380205 | 24.0 | 2.2% | 4,322,747 | Unchanged | |
| Design Therapeutics IncDSGN | Common | 25056L103 | 23.3 | 2.1% | 1,612,903 | Unchanged | |
| Oric Pharmaceuticals IncORIC | Common | 68622P109 | 20.0 | 1.8% | 1,848,786 | Unchanged | |
| CAMP4 Therapeutics CorporationCAMP | Common | 13463J101 | 18.6 | 1.7% | 4,246,568 | Unchanged | |
| Faeth Therapeutics IncFTH | Common | 81728A207 | 18.1 | 1.6% | 722,020 | Unchanged | |
| Achieve Life Sciences Inc.ACHV | Common | 004468500 | 18.0 | 1.6% | 2,751,032 | New+2,751,032 | |
| Compass Therapeutics IncCMPX | Common | 20454B104 | 17.0 | 1.6% | 7,757,060 | Reduced−1,788,406 | |
| AN2 Therapeutics IncANTX | Common | 037326105 | 15.3 | 1.4% | 3,153,640 | Unchanged | |
| Editas Medicine IncEDIT | Common | 28106W103 | 11.5 | 1.1% | 3,555,250 | New+3,555,250 | |
| Geron CorpGERN | Common | 374163103 | 11.1 | 1.0% | 8,671,797 | Unchanged | |
| Odyssey Therapeutics IncODTX | Common | 67613T104 | 10.8 | 1.0% | 575,000 | New+575,000 | |
| Eupraxia Pharmaceuticals IncEPRX | Common | 29842P105 | 8.9 | 0.8% | 1,350,000 | Unchanged | |
| Onkure Therapeutics IncOKUR | Common | 68277Q105 | 8.8 | 0.8% | 1,927,710 | Unchanged | |
| Olema Pharmaceuticals IncOLMA | Common | 68062P106 | 8.4 | 0.8% | 671,843 | Unchanged | |
| Monopar Therapeutics IncMNPR | Common | 61023L207 | 8.4 | 0.8% | 90,500 | Unchanged | |
| Aura Biosciences IncAURA | Common | 05153U107 | 8.3 | 0.8% | 1,166,667 | New+1,166,667 | |
| Surrozen IncSRZN | Common | 86889P208 | 6.7 | 0.6% | 260,000 | Unchanged | |
| ALX Oncology Holdings IncALXO | Common | 00166B105 | 6.6 | 0.6% | 3,184,713 | Unchanged | |
| Satellos Bioscience IncMSLE | Common | 80401L803 | 6.3 | 0.6% | 813,666 | Unchanged | |
| Avalo Therapeutics IncAVTX | Common | 05338F306 | 5.1 | 0.5% | 275,000 | New+275,000 | |
| Pepgen IncPEPG | Common | 713317105 | 4.2 | 0.4% | 2,325,000 | Unchanged | |
| Valneva SEVALN | SPONSORED ADS | 92025Y103 | 4.0 | 0.4% | 763,199 | New+763,199 | |
| Sera Prognostics IncSERA | Common | 81749D107 | 3.0 | 0.3% | 1,650,440 | Unchanged | |
| Unicycive TherapeuticsUNCY | Common | 90466Y202 | 2.6 | 0.2% | 550,000 | Reduced−1,239,916 | |
| Instil Bio IncTIL | Common | 45783C200 | 2.3 | 0.2% | 292,743 | Unchanged | |
| InMed Pharmaceuticals IncINM | Common | 457637700 | 1.2 | 0.1% | 798,377 | New+798,377 | |
| Bolt Biotherapeutics IncBOLT | Common | 097702203 | 0.3 | <0.1% | 72,414 | Unchanged | |
| Pasithea Therapeutics CorpKTTA | Common | 70261F202 | 0.2 | <0.1% | 465,471 | Reduced−1,634,529 | |
| Precision Biosciences IncDTIL | Common | 74019P207 | 0.0 | <0.1% | 4,675 | Unchanged |
Sold out: 6 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Cogent Biosciences IncCOGT | Common | 19240Q201 | 0.0 | 0.0% | 0 | Sold out−422,300 | |
| Compass Pathway PLCCMPS | SPONSORED ADS | 20451W101 | 0.0 | 0.0% | 0 | Sold out−200,000 | |
| Soleno Therapeutics Inc | Common | 834203309 | 0.0 | 0.0% | 0 | Sold out−294,909 | |
| Terns Pharmaceuticals Inc | Common | 880881107 | 0.0 | 0.0% | 0 | Sold out−1,334,418 | |
| Veradermics IncMANE | Common | 922967104 | 0.0 | 0.0% | 0 | Sold out−300,000 | |
| Viridian Therapeutics IncVRDN | Common | 92790C104 | 0.0 | 0.0% | 0 | Sold out−166,288 |
Source: SEC EDGAR, Form 13F-HR, accession 0001213900-26-089935 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.